Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Journal of Cellular Physiology|July 16, 2017
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life settingTeresa Gamucci, Laura Pizzuti, Isabella Sperduti, et al.
Cancers|August 10, 2024
DNA Damage Response in Early Breast Cancer: A Phase III Cohort in the Phobos StudyEriseld Krasniqi, Cristiana Ercolani, Anna Di Benedetto, et al.
Journal of Cellular Physiology|November 19, 2016
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast CancerTeresa Gamucci, Lucia Mentuccia, Clara Natoli, et al.
The Lancet. Oncology|February 28, 2018
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trialSabino De Placido, Ciro Gallo, Michelino De Laurentiis, et al.
The Lancet. Oncology|December 15, 2024
Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trialIcro Meattini, Maria Carmen De Santis, Luca Visani, et al.
Journal of the National Cancer Institute|July 5, 2022
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant TrastuzumabFrancesca Ligorio, Serena Di Cosimo, Paolo Verderio, et al.
International Journal of Medical Sciences|April 16, 2021
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS TrialEriseld Krasniqi, Laura Pizzuti, Maria Rosaria Valerio, et al.
Biology Direct|June 23, 2025
Multimodal deep learning for predicting neoadjuvant treatment outcomes in breast cancer: a systematic reviewEriseld Krasniqi, Lorena Filomeno, Teresa Arcuri, et al.
Cancer Biology & Therapy|January 17, 2018
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumabLaura Pizzuti, Domenico Sergi, Isabella Sperduti, et al.
Oncotarget|February 25, 2016
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcomePatrizia Vici, Laura Pizzuti, Isabella Sperduti, et al.
Pageof 10